Accretion Pharmaceuticals Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹201 Cr
The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue. Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.
From Accretion Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹202
Market Cap
₹201 Cr
P/E Ratio
20.8
Revenue Rank
Margin Rank
How does Accretion Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Accretion Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 1- →The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue.
- →Management indicated optimism for continued rapid sales growth in upcoming years, supported by a healthy order book and expanding export markets.
- →They anticipate leveraging newly added production capacity (with around a 40% capacity increase post-IPO), along with improved utilization and product mix, to drive volume growth.
- →FY '26 revenue is expected to surpass last year's INR57 crores significantly, aiming around INR120-130 crores based on current momentum.
- →The company plans to expand product registrations in new geographies (e.g., Rwanda, Nigeria, Cambodia) to bolster sales channels.
- →Growth is supported by strategic bulk sourcing, supply diversification, efficiency gains, and tighter working capital management.
- →While exact figures are not confirmed, management is confident in sustaining or improving existing growth rates going forward.
📈 Profitability & Margins
Rank 2- →Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.
- →The company anticipates EBITDA margins to improve from the current ~17% toward a steady-state of 20%-22%, as registration and scaling expenses normalize.
- →Profit after tax (PAT) is projected to grow significantly; with confidence expressed in maintaining or exceeding current profit levels (e.g., PAT closer to INR 10 crores anticipated).
- →Improved capacity utilization and expanded product registrations in multiple countries (e.g., Rwanda, Nigeria, Cambodia) will drive revenue and margin expansion.
- →Operational efficiencies, bulk sourcing, supply diversification, and tighter working capital management are expected to enhance profitability.
- →Long-term focus is on sustainable, profitable growth, value creation, and increasing return ratios supported by a healthy order book and strengthened balance sheet.
🏗️ Capital Expenditure Plans
Yes- →The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO.
- →The capex includes upgrading manufacturing facilities with new equipment to enhance capacity and compliance.
- →Future capex plans involve continued expansion and equipment upgradation to strengthen CDMO capabilities.
- →Focus on expanding product registrations and regulatory approvals in markets like Rwanda, Nigeria, Cambodia, and others to support growth.
- →Working capital has been augmented to support growing orders and ensure operational agility.
- →The company aims to sustain double-digit growth with a balanced mix of domestic and export revenues backed by these investments.
- →Loan repayments have reduced debt, maintaining a healthy capital structure with adequate liquidity for future expansions.
💰 Fundraising & Capital Structure
No information- →The company has recently completed a successful IPO in May 2025, raising INR29.75 crores.
- →Proceeds from the IPO have been strategically utilized for manufacturing facility upgrades, debt repayment, and working capital augmentation.
- →Short-term and long-term borrowings have drastically reduced due to loan repayments post-IPO.
- →There is no mention of any immediate or planned new fundraising through debt or equity in the call.
- →The company emphasizes maintaining a healthy capital structure with low debt-to-equity ratio and adequate liquidity for future expansion.
- →Focus remains on profitable growth, working capital efficiency, and prudent capital management without indicating any additional fundraising efforts currently.
📋 Order Book & Pipeline
Yes- →The company currently has a good order book, which supports their confidence in maintaining momentum in upcoming quarters.
- →They expect to sustain the growth rate seen in the first half of the year through efficient utilization of working capital and enhanced capacity.
- →New product launches and expansion into new countries also contribute to anticipated revenue growth from the order book.
- →The management confirms clarity on the existing order book and expects to deliver on these orders, contributing to PAT projections close to INR 10 crores for the year.
- →Although specific numbers are not disclosed, the company expresses confidence based on established products and customer relationships.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Accretion Pharmaceuticals Ltd Q2 FY26 results?
The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue. Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.
What is Accretion Pharmaceuticals Ltd share price analysis?
Accretion Pharmaceuticals Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 20.8 with a market cap of ₹201 Cr. Investors should review the full earnings analysis for detailed insights.
Is Accretion Pharmaceuticals Ltd planning capital expenditure?
The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO.
Keep Accretion Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.